Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 20/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 19/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151996 | 0.83 | HTR2A (0.59) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL7568036 | 0.83 | HTR2A (0.59) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL6152401 | 0.81 | HTR2A (0.59) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL6151592 | 0.80 | HTR2A (0.60) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL6151513 | 0.79 | HTR2A (0.70) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL6153430 | 0.79 | HTR2A (0.59) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL6152797 | 0.79 | SLC6A4 (0.59) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL6151710 | 0.78 | HTR2A (0.67) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL6151609 | 0.77 | HTR2A (0.71) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL6151381 | 0.77 | HTR2A (0.62) | HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147206-A1 | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | PFIZER INC. | 2002-10-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147206-A1 | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | PMP22, GAP43, SLC6A2 | HTR2A 108/4885SLC6A4 4/4885KCNH2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.